EUVIMEDEUVIMED entdecken
Open Access

Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti−PD-L1 in Cutaneous T-Cell Lymphoma

Zhen Han, Xiwei Wu, Hanjun Qin, Yate-Ching Yuan, Jasmine Zain, D Lynne Smith, Oleg E Akilov, Steven T Rosen, Mingye Feng, Christiane Querfeld

Journal of Investigative Dermatology · 2023

DOI: 10.1016/j.jid.2023.02.017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2023. Verfasst von Zhen Han und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Surgery, City of Hope, Duarte, California, USA; Beckman Research Institute, City of Hope, Duarte, California, …. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Cutaneous, Skin Neoplasms, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI, Leukemia and Lymphoma Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous T-cell lymphoma (CTCL) is an incurable and cosmetically disfiguring disease associated with microenvironmental signals. We investigated the effects of CD47 and PD-L1 immune checkpoint blockades, as a strategy for targeting both innate and adaptive immunity. CIBERSORT analysis identified the immune-cell composition in the CTCL tumor microenvironment and the immune checkpoint expression profile for each immune-cell gene cluster from CTCL lesions. We investigated the relationship between MYC and CD47 and PD-L1 expression and found that MYC short hairpin RNA knockdown and MYC functional suppression by TTI-621 (SIRPαFc) and anti-PD-L1 (durvalumab) in CTCL cell lines reduced the expression of CD47 and PDL1 mRNA and protein as measured by qPCR and flow cytometry, respectively. In vitro, blockade of the CD47-SIRPα interaction with TTI-621 increased the phagocytic activity of macrophages against CTCL cells and enhanced CD8+ T-cell-mediated killing in a mixed leucocyte reaction. Moreover, TTI-621 synergized with anti-PD-L1 in macrophages reprogram to M1-like phenotypes and inhibited CTCL cell growth. These effects were mediated by cell death-related pathways, including apoptosis, autophagy, and necroptosis. Collectively, our findings show that CD47 and PD-L1 are critical regulators of immune surveillance in CTCL and that dual targeting of CD47 and PD-L1 will provide insight into tumor immunotherapy for CTCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, T-Cell, CutaneousSkin NeoplasmsNeoplasmsHumansCD47 AntigenImmunoglobulin GImmunotherapyB7-H1 AntigenTumor Microenvironment

Substanzen

TTI-621CD47 AntigenImmunoglobulin GB7-H1 AntigenCD47 protein, human

Autor:innen und Institutionen

  • Division of Dermatology, Department of Surgery, City of Hope, Duarte, California, USA; Beckman Research Institute, City of Hope, Duarte, California, USA.
  • Beckman Research Institute, City of Hope, Duarte, California, USA; Integrative Genomics and Bioinformatics, City of Hope, Duarte, California, USA; Computational and Quantitative Medicine, City of Hope, Duarte, Californi…
  • Beckman Research Institute, City of Hope, Duarte, California, USA; Integrative Genomics and Bioinformatics, City of Hope, Duarte, California, USA.
  • Beckman Research Institute, City of Hope, Duarte, California, USA; Computational and Quantitative Medicine, City of Hope, Duarte, California, USA; Translational Bioinformatics, Center for informatics, City of Hope, Duar…
  • Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Cutaneous Lymphoma Program, Department of Dermatology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Förderung

  • NCI NIH HHS
  • NCI
  • Leukemia and Lymphoma Society
  • National Institutes of Health

Zitieren

APA

Han, Z., Wu, X., Qin, H., Yuan, Y. C., Zain, J., Smith, D. L., Akilov, O. E., Rosen, S. T., Feng, M., & Querfeld, C. (2023). Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti−PD-L1 in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2023.02.017

Vancouver

Han Z, Wu X, Qin H, Yuan YC, Zain J, Smith DL, et al. Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti−PD-L1 in Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology. 2023. doi:10.1016/j.jid.2023.02.017

BibTeX
@article{Han2023,
  author = {Han, Zhen and Wu, Xiwei and Qin, Hanjun and Yuan, Yate-Ching and Zain, Jasmine and Smith, D Lynne and Akilov, Oleg E and Rosen, Steven T and Feng, Mingye and Querfeld, Christiane},
  title = {Blockade of the Immune Checkpoint CD47 by TTI-621 Potentiates the Response to Anti−PD-L1 in Cutaneous T-Cell Lymphoma},
  journal = {Journal of Investigative Dermatology},
  year = {2023},
  doi = {10.1016/j.jid.2023.02.017}
}
Kostenlos starten →